Home › Compare › IRBL vs JNJ

IRBL vs JNJ: Dividend Comparison 2026

IRBL yields 2000000.00% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IRBL wins by $4.879226400974806e+39M in total portfolio value
10 years
IRBL
IRBL
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full IRBL calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — IRBL vs JNJ

📍 IRBL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIRBLJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IRBL + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IRBL pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IRBL
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, IRBL beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IRBL + JNJ for your $10,000?

IRBL: 50%JNJ: 50%
100% JNJ50/50100% IRBL
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

IRBL
No analyst data
Altman Z
-2.1
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IRBL buys
0
JNJ buys
0
No recent congressional trades found for IRBL or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIRBLJNJ
Forward yield2000000.00% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$4.879226400974806e+39M$20.0K ✓
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓$827.78
Total dividends collected$4.879195005460081e+39M$5.6K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IRBL vs JNJ ($10,000, DRIP)

YearIRBL PortfolioIRBL Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$200,010,700$200,000,000.00$10,676$355.77+$200.00M → IRBL
2$3,738,731,768,458$3,738,517,757,009.35$11,407$389.39+$3738731.76M → IRBL
3$65,315,062,866,930,490$65,311,062,423,938,240.00$12,198$426.53+$65315062866.92M → IRBL
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$13,056$467.62+$1066400830062625.00M → IRBL
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$13,987$513.12+$16272182796453826560.00M → IRBL
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$14,998$563.56+$2.3205424011366188e+23M → IRBL
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$16,098$619.52+$3.0927990661046884e+27M → IRBL
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$17,295$681.69+$3.8524105697352695e+31M → IRBL
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$18,599$750.82+$4.484688260147987e+35M → IRBL
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$20,022$827.78+$4.879226400974806e+39M → IRBL

IRBL vs JNJ: Complete Analysis 2026

IRBL — Stock

InRob Tech Ltd. provides engineering products and services for the maintenance of equipment, and the integration and production of wireless control solutions for unmanned ground vehicle robots (UVR) for military and law enforcement UVR applications and control solutions. The company's UVR solutions comprise remote control systems, complete robot systems, and customized solutions. It also targets the civilian applications market, which includes solar powered equipment, as well as nuclear plant maintenance, inspection, and decommissioning; the demolition industry; and firefighting and rescue services. The company is based in Las Vegas, Nevada.

Full IRBL Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this IRBL vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IRBL vs SCHDIRBL vs JEPIIRBL vs OIRBL vs KOIRBL vs MAINIRBL vs ABBVIRBL vs MRKIRBL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.